Clinical Trial Update: Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating genetically modified T cells for stage III-IV non-small cell lung cancer and mesothelioma; study terminated with posted results in…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pleural Malignant Mesothelioma

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Advanced Pleural Malignant Mesothelioma, HLA-A*0201 Positive Cells Present | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-09-13